247 related articles for article (PubMed ID: 30213328)
21. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
[TBL] [Abstract][Full Text] [Related]
22. Relation of the SAMe-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials.
Proietti M; Lane DA; Lip GY
Int J Cardiol; 2016 Aug; 216():168-72. PubMed ID: 27156060
[TBL] [Abstract][Full Text] [Related]
23. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement.
Abdul-Jawad Altisent O; Durand E; Muñoz-García AJ; Nombela-Franco L; Cheema A; Kefer J; Gutierrez E; Benítez LM; Amat-Santos IJ; Serra V; Eltchaninoff H; Alnasser SM; Elízaga J; Dager A; García Del Blanco B; Ortas-Nadal Mdel R; Marsal JR; Campelo-Parada F; Regueiro A; Del Trigo M; Dumont E; Puri R; Rodés-Cabau J
JACC Cardiovasc Interv; 2016 Aug; 9(16):1706-17. PubMed ID: 27539691
[TBL] [Abstract][Full Text] [Related]
24. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial fibrillation and cognitive impairment.
Gorzelak-Pabiś P; Zyzak S; Krewko Ł; Broncel M
Pol Arch Med Wewn; 2016 Aug; 126(7-8):494-501. PubMed ID: 27511466
[TBL] [Abstract][Full Text] [Related]
26. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Marin F; Gálvez J; Valdés M; Vicente V; Lip GYH
Am J Med; 2014 Nov; 127(11):1083-1088. PubMed ID: 24858062
[TBL] [Abstract][Full Text] [Related]
27. Quality of Anticoagulation With Vitamin K Antagonists.
Bertomeu-González V; Anguita M; Moreno-Arribas J; Cequier Á; Muñiz J; Castillo-Castillo J; Sanchis J; Roldán I; Marin F; Bertomeu-Martínez V;
Clin Cardiol; 2015 Jun; 38(6):357-64. PubMed ID: 25962838
[TBL] [Abstract][Full Text] [Related]
28. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland.
Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H
Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622
[TBL] [Abstract][Full Text] [Related]
29. Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study.
Staerk L; Fosbøl EL; Lamberts M; Bonde AN; Gadsbøll K; Sindet-Pedersen C; Holm EA; Gerds TA; Ozenne B; Lip GYH; Torp-Pedersen C; Gislason GH; Olesen JB
Eur Heart J; 2018 May; 39(19):1698-1705a. PubMed ID: 29165556
[TBL] [Abstract][Full Text] [Related]
30. [Management of thromboembolic risk in patients with atrial fibrillation in Italy: follow-up data from the PREFER in AF European Registry].
Renda G; Patti G; Sangiuolo R; Attena E; Malpezzi MG; De Caterina R;
G Ital Cardiol (Rome); 2016 Nov; 17(11):922-931. PubMed ID: 27996998
[TBL] [Abstract][Full Text] [Related]
31. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
[TBL] [Abstract][Full Text] [Related]
32. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.
Pokorney SD; Simon DN; Thomas L; Fonarow GC; Kowey PR; Chang P; Singer DE; Ansell J; Blanco RG; Gersh B; Mahaffey KW; Hylek EM; Go AS; Piccini JP; Peterson ED;
Am Heart J; 2015 Jul; 170(1):141-8, 148.e1. PubMed ID: 26093875
[TBL] [Abstract][Full Text] [Related]
33. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.
Razouki Z; Ozonoff A; Zhao S; Jasuja GK; Rose AJ
Circ Cardiovasc Qual Outcomes; 2014 Sep; 7(5):664-9. PubMed ID: 25185245
[TBL] [Abstract][Full Text] [Related]
34. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.
Olesen JB; Lip GY; Lindhardsen J; Lane DA; Ahlehoff O; Hansen ML; Raunsø J; Tolstrup JS; Hansen PR; Gislason GH; Torp-Pedersen C
Thromb Haemost; 2011 Oct; 106(4):739-49. PubMed ID: 21789337
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB;
Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971
[TBL] [Abstract][Full Text] [Related]
36. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
[TBL] [Abstract][Full Text] [Related]
37. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
[TBL] [Abstract][Full Text] [Related]
38. Association Between Inappropriately Dosed Anticoagulation Therapy With Stroke Severity and Outcomes in Patients With Atrial Fibrillation.
Vinding NE; Butt JH; Olesen JB; Xian Y; Kristensen SL; Rørth R; Bonde AN; Gundlund A; Yafasova A; Weeke PE; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
J Am Heart Assoc; 2022 Mar; 11(6):e024402. PubMed ID: 35229642
[TBL] [Abstract][Full Text] [Related]
39. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists.
Abumuaileq RR; Abu-Assi E; Raposeiras-Roubin S; López-López A; Redondo-Diéguez A; Álvarez-Iglesias D; Rodríguez-Mañero M; Peña-Gil C; González-Juanatey JR
Europace; 2015 May; 17(5):711-7. PubMed ID: 25662984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
